NPF Statement About the CERE-120 Growth Factor Trial

Release date: 4/20/2013

Read NPF's statement regarding data from Ceregene's Parkinson's disease study.

The announcement of the CERE-120 growth factor trial (Neurturin) has been made public.  Though the trial was negative, scientists believe they have learned important information for the field about this class of compounds known as neurotrophic factors.  More information on the specifics of this trial will be available soon, as the study will be published in a major medical journal.  Though the results of the trial were negative, this should not diminish our enthusiasm for the multitude of other potential new therapies being researched across the globe.

Read the full press release from Ceregene.

Print